The interest from potential partners has, according to the Board and management, increased significantly after Alzinova presented its positive data from the first part of the phase 1b study. This was emphasized not least at the recent US BIO Congress in San Diego, which was held in June, and at the Alzheimer's Association International Conference, AAIC, held in Philadelphia at the end of July/beginning of August 2024.

To accelerate and further optimize the process of finding the right partner for ALZ-101, Alzinova has also engaged a renowned US Investment Bank, M&A and advisory firm to assist the company in identifying and subsequently signing a partner agreement. The bank has extensive experience in M&A in the pharmaceutical industry and has advised on previous closed transactions in the same segment. The process is already in full motion.

The focus on the Alzheimer's segment from the industry has increased strongly recently, specifically the demand for new and innovative treatments with a favourable safety profile. The company’s candidate ALZ-101 is well positioned in the market, which is also supported by the recent business activities in the field, including early-stage vaccine candidates.

The company intends to update the stock market on the progress of the process.